贝伐珠单抗单药及联合伊立替康治疗复发性胶质母细胞瘤
这项II期、多中心、开放标签、非对照试验将167例复发性胶质母细胞瘤患者随机分配接受贝伐珠单抗单药或联合伊立替康治疗。单药组与联合组6个月无进展生存率分别为42.6%和50.3%,客观缓解率分别为28.2%和37.8%,中位总生存期分别为9.2个月和8.7个月。结论认为贝伐珠单抗单药或联合伊立替康耐受良好且具有活性。
要点
- 贝伐珠单抗单药组6个月无进展生存率42.6%,联合伊立替康组50.3%。
- 单药组客观缓解率28.2%,联合组37.8%。
- 单药组46.4%、联合组65.8%发生≥3级不良事件。
核心结论
- 贝伐珠单抗单药或联合伊立替康在复发性胶质母细胞瘤中耐受良好且具有活性。
研究设计与样本
- II期、多中心、开放标签、非对照试验,167例复发性胶质母细胞瘤患者随机接受贝伐珠单抗10 mg/kg单药或联合伊立替康340 mg/m2或125 mg/m2(分别用于合用或不合用酶诱导性抗癫痫药者),每2周一次。
- 主要终点为独立放射学评估的6个月无进展生存率和客观缓解率,次要终点包括安全性和总生存期。
主要发现
- 贝伐珠单抗单药组与联合伊立替康组的估计6个月无进展生存率分别为42.6%和50.3%。
- 单药组与联合组的客观缓解率分别为28.2%和37.8%。
- 单药组与联合组的中位总生存期分别为9.2个月和8.7个月。
- 基线使用皮质类固醇的患者有维持稳定或逐渐减量的趋势。
- 单药组46.4%、联合组65.8%发生≥3级不良事件;单药组最常见为高血压(8.3%)和惊厥(6.0%),联合组为惊厥(13.9%)、中性粒细胞减少(8.9%)和乏力(8.9%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated the efficacy of bevacizumab, alone and in combination with irinotecan, in patients with recurrent glioblastoma in a phase II, multicenter, open-label, noncomparative trial. PATIENTS AND METHODS: One hundred sixty-seven patients were randomly assigned to receive bevacizumab 10 mg/kg alone or in combination with irinotecan 340 mg/m2 or 125 mg/m2 (with or without concomitant enzyme-inducing antiepileptic drugs, respectively) once every 2 weeks. Primary end points were 6-month progression-free survival and objective response rate, as determined by independent radiology review. Secondary end points included safety and overall survival. RESULTS: In the bevacizumab-alone and the bevacizumab-plus-irinotecan groups, estimated 6-month progression-free survival rates were 42.6% and 50.3%, respectively; objective response rates were 28.2% and 37.8%, respectively; and median overall survival times were 9.2 months and 8.7 months, respectively. There was a trend for patients who were taking corticosteroids at baseline to take stable or decreasing doses over time. Of the patients treated with bevacizumab alone or bevacizumab plus irinotecan, 46.4% and 65.8%, respectively, experienced grade ≥ 3 adverse events, the most common of which were hypertension (8.3%) and convulsion (6.0%) in the bevacizumab-alone group and convulsion (13.9%), neutropenia (8.9%), and fatigue (8.9%) in the bevacizumab-plus-irinotecan group. Intracranial hemorrhage was noted in two patients (2.4%) in the bevacizumab-alone group (grade 1) and in three patients (3.8%) patients in the bevacizumab-plus-irinotecan group (grades 1, 2, and 4, respectively). CONCLUSION: Bevacizumab, alone or in combination with irinotecan, was well tolerated and active in recurrent glioblastoma.
引用
- Friedman HS, Prados MD, Wen PY, et al. Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. J Clin Oncol. 2023. PMID: 37935104. doi:10.1200/JCO.22.02772
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。